Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients. The company was founded in 2016 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone646-998-6475
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.76 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date10/30/2019 (Estimated)
OptionableNot Optionable
Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions
What is Seelos Therapeutics' stock symbol?
Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."
How were Seelos Therapeutics' earnings last quarter?
Seelos Therapeutics Inc (NASDAQ:SEEL) announced its quarterly earnings results on Thursday, August, 1st. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.04. View Seelos Therapeutics' Earnings History.
When is Seelos Therapeutics' next earnings date?
What price target have analysts set for SEEL?
2 brokerages have issued twelve-month price targets for Seelos Therapeutics' shares. Their predictions range from $4.00 to $8.00. On average, they expect Seelos Therapeutics' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 545.2% from the stock's current price. View Analyst Price Targets for Seelos Therapeutics.
What is the consensus analysts' recommendation for Seelos Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seelos Therapeutics.
Has Seelos Therapeutics been receiving favorable news coverage?
Media stories about SEEL stock have been trending somewhat positive recently, according to InfoTrie. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Seelos Therapeutics earned a news impact score of 0.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Seelos Therapeutics.
Are investors shorting Seelos Therapeutics?
Seelos Therapeutics saw a drop in short interest in September. As of September 15th, there was short interest totalling 573,800 shares, a drop of 29.6% from the August 15th total of 815,200 shares. Based on an average daily trading volume, of 486,600 shares, the days-to-cover ratio is currently 1.2 days. Currently, 3.1% of the shares of the company are sold short. View Seelos Therapeutics' Current Options Chain.
Who are some of Seelos Therapeutics' key competitors?
Some companies that are related to Seelos Therapeutics include NeuBase Therapeutics (NBSE), Galmed Pharmaceuticals (GLMD), Verastem (VSTM), Aquestive Therapeutics (AQST), Vaccinex (VCNX), Humanigen (HGEN), Cumberland Pharmaceuticals (CPIX), Mersana Therapeutics (MRSN), Neoleukin Therapeutics (NLTX), vTv Therapeutics (VTVT), Lipocine (LPCN), Entasis Therapeutics (ETTX), Checkpoint Therapeutics (CKPT), Aravive (ARAV) and IMMUTEP LTD/S (IMMP).
What other stocks do shareholders of Seelos Therapeutics own?
Who are Seelos Therapeutics' key executives?
Seelos Therapeutics' management team includes the folowing people:
- Dr. Raj Mehra Ph.D., Chairman, CEO, Pres & Interim CFO (Age 59)
Who are Seelos Therapeutics' major shareholders?
Seelos Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.36%).
Which institutional investors are buying Seelos Therapeutics stock?
SEEL stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..
How do I buy shares of Seelos Therapeutics?
Shares of SEEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Seelos Therapeutics' stock price today?
One share of SEEL stock can currently be purchased for approximately $0.93.
How big of a company is Seelos Therapeutics?
What is Seelos Therapeutics' official website?
How can I contact Seelos Therapeutics?
Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company can be reached via phone at 646-998-6475 or via email at [email protected]
MarketBeat Community Rating for Seelos Therapeutics (NASDAQ SEEL)
MarketBeat's community ratings are surveys of what our community members think about Seelos Therapeutics and other stocks. Vote "Outperform" if you believe SEEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SEEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
